Loss in Life Expectancy after Surgical Aortic Valve Replacement

This study found after surgical aortic valve replacement (SAVR) patients had shorter life expectancy, compared against the general population. This loss in life expectancy was significant, especially in young patients. These results provide essential information to advice patients before and after SAVR.

Remodelado miocárdico reverso luego del reemplazo valvular

This is an observational national cohort study to assess long term relative survival and estimated loss in life expectancy after SAVR.

The study included 23528 patients undergoing SAVR with or without concomitant myocardial revascularization surgery in Sweden between 1995 and 2013 from the registry SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies). Life expectancy of the Swedish general population was estimated and matched by sex, age and year of surgery.

Over 19 years, researchers observed 21%, with and expected survival of 34%, and 63% relative survival. Loss in life expectancy was 1.9 years for the study population but varied with age. ≥80 patients only lost 0.4 years vs. 4.4 in <50 year olds.


Read also: Clinical Implications of the New Hypertension Guidelines.


There were no differences between men and women.

Conclusion

Patients undergoing surgical aortic valve replacement lose life expectancy compared against the general population, significantly, and especially the younger patients. This information is relevant to better advice our patients before and after SAVR.

Original Title: Loss in Life Expectancy After Surgical Aortic Valve Replacement. SWEDEHEART Study.

Reference: Natalie Glaser et al. J Am Coll Cardiol 2019;74:26–33.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026 | CHAMPION-AF: Left atrial appendage closure versus anticoagulation in atrial fibrillation

Can left atrial appendage closure challenge anticoagulation as the standard of care in atrial fibrillation? Atrial fibrillation (AF) is the most common sustained arrhythmia and...

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHAMPION-AF: Left atrial appendage closure versus anticoagulation in atrial fibrillation

Can left atrial appendage closure challenge anticoagulation as the standard of care in atrial fibrillation? Atrial fibrillation (AF) is the most common sustained arrhythmia and...

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...